ARCT Arcturus Therapeutics Holdings Inc.

50.71
-1.87  -4%
Previous Close 52.58
Open 51.41
52 Week Low 8.51
52 Week High 66.24
Market Cap $1,241,025,931
Shares 24,473,002
Float 18,877,887
Enterprise Value $1,171,469,445
Volume 313,645
Av. Daily Volume 630,884
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
LUNAR-COV19
COVID-19 vaccine
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ARCT-810
Ornithine Transcarbamylase (OTC) deficiency
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. LUNAR® lipids undetectable in plasma 48 hours following drug administration

    ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4

    Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the completion of the first three dose escalation cohorts in its ongoing Phase 1 study with ARCT-810, the Company's messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.

    The…

    LUNAR® lipids undetectable in plasma 48 hours following drug administration

    ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4

    Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the completion of the first three dose escalation cohorts in its ongoing Phase 1 study with ARCT-810, the Company's messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.

    The ARCT-810 Phase 1 study is a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers. The study has completed three cohorts in total and the fourth cohort is expected to complete this quarter. All cohorts are randomized 2:1 active to placebo and the study is designed to evaluate safety and tolerability, and pharmacokinetics, as primary and secondary endpoints.

    All subjects in cohorts up to 0.3 mg/kg have completed dosing and all study visits. Based on the available preliminary study data, ARCT-810 has been well tolerated at these doses, which are all within the anticipated therapeutic range. All adverse events observed have been mild or moderate in nature and there have been no serious adverse events. ARCT-810 has demonstrated a favorable pharmacokinetic profile, and no ARCT-810 lipid was detectable in plasma beyond 48 hours following drug administration. The company plans to report final data following study completion, which is anticipated this quarter.

    "We are pleased to have made rapid progress advancing our Phase 1 study for ARCT-810, a highly promising mRNA-based therapeutic candidate for OTC deficiency. Preliminary safety and pharmacokinetic data are favorable and supportive of continued development," said Steve Hughes, M.D., Chief Development Officer of Arcturus. "Administration at the highest dose cohort is ongoing and we anticipate study completion later this quarter. Our second ARCT-810 clinical study in patients with OTC deficiency is now recruiting and we expect to begin dosing patients at a U.S. clinical site this quarter."

    About ARCT-810

    ARCT-810 utilizes Arcturus' LUNAR® lipid-mediated delivery platform to deliver OTC messenger RNA to liver cells. Expression of ornithine transcarbamylase enzyme in the liver of patients with OTC deficiency has the potential to restore normal urea cycle activity, preventing neurological damage and the need for liver transplantation. The ARCT-810 program is supported by preclinical data in OTC deficiency murine models demonstrating that dosing of LUNAR-OTC results in robust ornithine transcarbamylase protein expression and activity resulting in improvements in ureagenesis and plasma ammonia, and increased survival.

    About Arcturus Therapeutics

    Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (198 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

    Forward Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company's expected performance, the Company's development of any specific mRNA therapeutics or vaccines, the likelihood of success, efficacy or safety of ARCT-810, the likelihood that ARCT-810 preclinical data or existing clinical data will be predictive of future clinical data, the likelihood that available preliminary study data will be predictive of the full data sets when available, the expected dose size of ARCT-810, the timing or success of, or ability to initiate or complete, the current Phase 1 study for ARCT-810 or future clinical studies of ARCT-810, are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus' Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

    View Full Article Hide Full Article
  2. Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present virtually at the upcoming conference:

    • Guggenheim's 1st Annual Vaccines and Infectious Diseases Conference
      Fireside Chat
      Date: Monday, October 5, 2020
      Time: 3:45 p.m. ET

    About Arcturus Therapeutics
    Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA…

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present virtually at the upcoming conference:

    • Guggenheim's 1st Annual Vaccines and Infectious Diseases Conference

      Fireside Chat

      Date: Monday, October 5, 2020

      Time: 3:45 p.m. ET

    About Arcturus Therapeutics

    Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

    View Full Article Hide Full Article
  3. SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually:

    • TIDES: Oligonucleotide and Peptide Therapeutics scientific conference
      Presentation
      Date: Wednesday, September 9, 2020
      Time: On-line

    • Baird Global Healthcare Conference
      Presentation
      Date: Wednesday, September 9, 2020
      Time: 1:25 p.m. ET

    • Citi 15th Annual BioPharma Conference
      Panel
      Date: Thursday, September 10, 2020
      Time: 1:30 p.m…

    SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually:

    • TIDES: Oligonucleotide and Peptide Therapeutics scientific conference

      Presentation

      Date: Wednesday, September 9, 2020

      Time: On-line



    • Baird Global Healthcare Conference

      Presentation

      Date: Wednesday, September 9, 2020

      Time: 1:25 p.m. ET



    • Citi 15th Annual BioPharma Conference

      Panel

      Date: Thursday, September 10, 2020

      Time: 1:30 p.m. ET



    • UBS COVID-19 Vaccine Symposium

      Fireside Chat

      Date: Friday, September 11, 2020

      Time: 3:50 p.m. ET



    • H.C. Wainwright & Co. 22nd Annual Global Investment Conference

      Presentation

      Date: Monday, September 14, 2020

      Time: 11:00 a.m. ET

    The events above may be accessed on the Arcturus website in the Investors Relation section, under Events and Presentations for approximately 30 days following the events.

    About Arcturus Therapeutics

    Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com

    IR and Media Contacts

    Arcturus Therapeutics

    Neda Safarzadeh

    (858) 900-2682

    Kendall Investor Relations

    Carlo Tanzi, Ph.D.

    (617) 914-0008 

    Primary Logo

    View Full Article Hide Full Article
  4. Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination

    Clinical study remains on track, initial data readout expected Q4 2020

    SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that its manuscript is now available on an online preprint server at Bioarchive and is concurrently undergoing scientific peer review. The manuscript provides an in-depth…

    Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination

    Clinical study remains on track, initial data readout expected Q4 2020

    SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that its manuscript is now available on an online preprint server at Bioarchive and is concurrently undergoing scientific peer review. The manuscript provides an in-depth assessment of humoral- and cell-mediated immune activation following a single shot vaccination in mice and shows that LUNAR®-COV19 (ARCT-021) produced robust antibody responses, with neutralizing antibody titers increasing up to day 60.  In addition, single doses of LUNAR®-COV19 at both the 2 μg and 10 μg levels completely protected human ACE2 transgenic mice from both mortality and even measurable infection following wild-type SARS-CoV-2 challenge. The Company believes that the findings from this study, which was conducted in collaboration with Duke-NUS Medical School, collectively suggest the potential of LUNAR®-COV19 as a single dose vaccine. The Company is currently evaluating LUNAR®-COV19 in a Phase 1/2 clinical study.

    The publication: de Alwis et al., A Single Prime Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccination Produces Protective Adaptive Immunity is available on the Bioarchive website https://www.biorxiv.org/content/10.1101/2020.09.03.280446v1

    "The data we have in preprint at Bioarchive continues to provide strong support for the potent immunogenicity of LUNAR®-COV19. Results demonstrate that a single vaccination in mice led to robust antibody responses, with neutralizing antibody titers increasing up to day 60. Furthermore, activation of cell mediated immunity produced a strong viral antigen specific CD8+ T lymphocyte response and a desirable Th1 dominant immune response. Importantly, a single LUNAR®-COV19 vaccination at very low microgram doses resulted in complete protection from infection and death from SARS-CoV-2 in a transgenic human ACE2 mouse challenge model, with no detectable virus present in LUNAR®-COV19 vaccinated mice," said Professor Ooi Eng Eong, Deputy Director, Emerging Infectious Diseases Programme, Duke-NUS Medical School and a member of Arcturus' Vaccine Platform Scientific Advisory Board.

    "Our findings highlight the potential of LUNAR®-COV19 to be a highly potent, low dose, single shot vaccine. These favorable attributes may provide a substantial benefit compared to the multiple vaccine dosing regimens that are more commonly being developed. We believe that this advantageous profile could greatly facilitate the mass vaccination campaigns necessary to control the global COVID-19 pandemic," said Pad Chivukula, Ph.D., CSO & COO of Arcturus.

    About STARR™ Technology

    The STARR™ Technology platform combines self-replicating RNA with LUNAR®, a leading nanoparticle delivery system, into a single solution to produce proteins inside the human body.  The versatility of the STARR™ Technology enables it upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. The self-replicating RNA-based prophylactic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens. This combination of the LUNAR® and STARR™ technology is expected to provide lower dose requirements due to superior immune response, sustained protein expression compared to non-self-replicating RNA-based vaccines and potentially enabling to produce vaccines more quickly and simply.

    About Arcturus Therapeutics

    Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com

    Forward Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company's efforts to develop a vaccine against COVID-19, and therapeutic potential thereof, based on the Company's mRNA therapeutics, the Company's ongoing Phase 1/2 and availability of expected results, the potential of the vaccine against COVID-19 as a single dose vaccine and the impact of general business and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus' Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. No assurances can be given that any results reported in pre-clinical studies can be replicated in further studies or in human beings, or that a vaccine can or will ever be developed or approved using the Company's technology. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

    IR and Media Contacts

    Arcturus Therapeutics

    Neda Safarzadeh

    (858) 900-2682

     

    Kendall Investor Relations

    Carlo Tanzi, Ph.D.

    (617) 914-0008 

     

    Primary Logo

    View Full Article Hide Full Article
  5. SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health, to supply COVID-19 STARR™ mRNA vaccine candidate (ARCT-021). Delivery to Israel of doses of Arcturus' COVID-19 vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones.

    "We are pleased to have executed the definitive supply…

    SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health, to supply COVID-19 STARR™ mRNA vaccine candidate (ARCT-021). Delivery to Israel of doses of Arcturus' COVID-19 vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones.

    "We are pleased to have executed the definitive supply agreement with the Israeli Ministry of Health. Arcturus is honored to play a key role in Israel's COVID-19 vaccination strategy.  As indicated in a recent press conference on July 23rd, led by Prime Minister Netanyahu, this is considered a significant deal to the government of Israel, providing them rights and access to ARCT-021 and a path to potentially vaccinate a substantial portion of their citizens against coronavirus," said Joseph Payne, President & CEO of Arcturus. "We value the Israeli Ministry of Health's commitment to our differentiating STARR™ mRNA vaccine candidate and we look forward to advancing the development of ARCT-021."

    Israel is the second country, in addition to Singapore, to reserve supply of the ARCT-021 vaccine. Arcturus is in active discussions with certain government entities in major markets and other parts of the world. With the Company's manufacturing partners, Arcturus is in the process of manufacturing millions of doses in 2020 and positioned to supply hundreds of millions of doses annually thereafter.

    For more information about rights and access to Arcturus' COVID-19 vaccine candidate, ARCT-021, please contact Arcturus at .

    About STARR™ Technology

    The STARR™ Technology platform combines self-replicating RNA with LUNAR®, a leading nanoparticle delivery system, into a single solution to produce proteins inside the human body.  The versatility of the STARR™ Technology affords its ability upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. The self-replicating RNA-based therapeutic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens. This combination of the LUNAR® and STARR™ technology is expected to provide lower dose requirements due to superior immune response, sustained protein expression compared to non-self-replicating RNA-based vaccines and potentially enable us to produce vaccines more quickly and simply.

    About Arcturus Therapeutics

    Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com.

    Forward Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company's efforts to develop a vaccine against COVID-19, and therapeutic potential thereof, based on the Company's mRNA therapeutics, the ability of the Company to scale up manufacturing of vaccine doses, regulatory approval of the vaccine against COVID-19, the potential supply of the vaccine to government entities in major markets and other parts of the world and the impact of general business and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus' Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. No assurances can be given that any results reported in pre-clinical studies can be replicated in further studies or in human beings, or that a vaccine can or will ever be developed or approved using the Company's technology. A more fulsome description of the definitive supply agreement will be included with the current report on Form 8-K to be filed by the Company with the SEC.  Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

    IR and Media Contacts

    Arcturus Therapeutics

    Neda Safarzadeh

    (858) 900-2682

    Kendall Investor Relations

    Carlo Tanzi, Ph.D.

    (617) 914-0008 

    Primary Logo

    View Full Article Hide Full Article
View All Arcturus Therapeutics Holdings Inc. News